StumpsOfMystery Friday, 10/18/19 07:05:17 PM Re: 59SC post# 3622 Post # of 4201 I really appreciate your at least topically respectful tone. Although I expect you mean to lure me into errors you will refute. If you are actually interested in answers, I do not have them. Not a specialist in this area. There are many hemostatic devices on the market--not just Surgigel. I would guess that the value of this product would have to do with any competitive advantage using it would give to one of the current producers over the rest of the market. It would be my guess that that advantage would have to be substantial. In other words, maybe 25% or more improvement overall against Surgigel. What additional sales would be made given the improvement? How would medical authorities respond to the introduction of a relatively 'new' product? Particularly one offered by a company with a somewhat questionable pedigree, with no recent revenues and facing 3 current lawsuits? (After all, anyone USING Hemostype would need to be reasonably sure the company backing it were financially secure). What would be the cost of a takeover? At the current market capitalization of $250M I would doubt many companies would feel it were worth the cost, to be honest. Anyway, those are a few of my thoughts. I had promised another member to cease posting here as several are irked by my considerations. I may respond again if you ask questions. GLTA.